Congress recently began hearings on proposals to combat opioid abuse. Our policy analyst weighs in.
Pharmacy Best Practices
Experts say this new migraine medication, the first in 50 years, shows great promise. Here’s what you need to know, including the cost implications
The new Bipartisan Budget Act of 2018, to be in effect on January 2019, institutes new reimbursement guidelines for biosimilars under the Medicare coverage gap discount program that remove disincentives for biosimilar uptake and level the playing field for the future market place.
How skipping industry acronyms and jargon and using simple terminology will eliminate confusion and misinterpretation.
A Surescripts survey reveals the need for more interoperable access to patient data in three major areas.
An ONC report finds that more patients are engaged with their health records. Here’s why.
The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.
Expiring patents and biosimilar developments are creating big market opportunities within the specialty drug space.
High-cost treatments for rheumatoid arthritis has fueled the need to better understand their value to healthcare systems and patients.
Drug makers and payers have these challenges to implement outcomes-based contracts, but here are three steps that can be taken as a transition toward these payment arrangements.